(3-甲基-5-硝基吡啶-2-基)肼 | 6965-63-5

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: (3-甲基-5-硝基吡啶-2-基)肼
• 英文名称: 2-hydrazinyl-3-methyl-5-nitropyridine
• 英文别名: 2-hydrazino-3-methyl-5-nitro-pyridine；2-Hydrazino-3-methyl-5-nitro-pyridin；(3-methyl-5-nitropyridin-2-yl)hydrazine
• CAS: 6965-63-5
• 化学式: C₆H₈N₄O₂
• 分子量: 168.155
• InChiKey: CSHKMLIZQJQZBQ-UHFFFAOYSA-N

物化性质

• 熔点：
  177 °C(Solv: ethanol (64-17-5))
• 沸点：
  273.9±43.0 °C(Predicted)
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.58
• 重原子数：
  12.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  94.08
• 氢给体数：
  2.0
• 氢受体数：
  5.0

安全信息

• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Hydrazinyl-3-methyl-5-nitropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Hydrazinyl-3-methyl-5-nitropyridine
CAS number: 6965-63-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H8N4O2
Molecular weight: 168.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (3-甲基-5-硝基吡啶-2-基)肼 在 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 、 三乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 为溶剂， 20.0~30.0 ℃ 、400.01 kPa 条件下， 反应 3.67h， 生成 3,8-dimethyl-[1,2,4]-triazolo[4,3-a]pyridin-6-amine
  参考文献：
  名称：

  [EN] PYRROLOPYRROLONE DERIVATIVES AND THEIR USE AS BET INHIBITORS
  [FR] DÉRIVÉS DE PYRROLOPYRROLONE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE PROTÉINES BET

  摘要：

  本发明提供了一种化合物的化学式(I)或其药用盐；一种制造本发明化合物的方法，以及其治疗用途。本发明还提供了药理活性剂的组合和药物组成。

  公开号：

  WO2015075665A1
• 作为产物：
  描述：

  2-氯-3-甲基-5-硝基吡啶 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以95%的产率得到(3-甲基-5-硝基吡啶-2-基)肼
  参考文献：
  名称：

  [EN] PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE
  [FR] DÉRIVÉS DE PYRAZOLOPYRROLIDINE-4-ONE EN TANT QU'INHIBITEURS DE BET ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES

  摘要：

  本发明提供了化合物(I)或其药学上可接受的盐；(l)本发明化合物的制备方法及其治疗用途。本发明还提供了药理活性剂的组合和制药组合物。

  公开号：

  WO2014191906A1

文献信息

• [EN] PYRAZOLO-PYRROLIDIN-4-ONE DERIVATIVES AS BET INHIBITORS AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] DÉRIVÉS DE PYRAZOLOPYRROLIDINE-4-ONE EN TANT QU'INHIBITEURS DE BET ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
  申请人：NOVARTIS AG

  公开号：WO2014191906A1

  公开（公告）日：2014-12-04

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; (l) a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物(I)或其药学上可接受的盐；(l)本发明化合物的制备方法及其治疗用途。本发明还提供了药理活性剂的组合和制药组合物。
• [EN] IMIDAZOPYRROLIDINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] DÉRIVÉS IMIDAZOPYRROLIDINONE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
  申请人：NOVARTIS AG

  公开号：WO2014191894A1

  公开（公告）日：2014-12-04

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物(I)或其药学上可接受的盐；制造本发明化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合和药物组合物。
• Pyrazolopyrrolidine Derivatives and their Use in the Treatment of Disease
  申请人：BLANK Jutta

  公开号：US20140349990A1

  公开（公告）日：2014-11-27

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物的公式(I)或其药用盐；制备本发明化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合和制药组合物。
• [EN] PYRAZOLOPYRROLIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE<br/>[FR] NOUVEAUX DÉRIVÉS PYRAZOLOPYRROLIDINE ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES
  申请人：NOVARTIS AG

  公开号：WO2014191896A1

  公开（公告）日：2014-12-04

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了化合物的公式(I)或其药学上可接受的盐；制备本发明化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合和药物组合物。
• Pyrazolopyrrolidine derivatives and their use in the treatment of disease
  申请人：Bordas Vincent

  公开号：US08975417B2

  公开（公告）日：2015-03-10

  The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了式（I）的化合物或其药学上可接受的盐；制造本发明化合物的方法及其治疗用途。本发明还提供了药理活性剂的组合和制药组合物。